Amgen Inc. $AMGN Stake Lessened by Wilkinson Global Asset Management LLC

Posted by Brian Himes on Aug 18th, 2026

Wilkinson Global Asset Management LLC trimmed its stake in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 26.9% during the second quarter, HoldingsChannel reports. The fund owned 136,508 shares of the medical research company’s stock after selling 50,357 shares during the quarter. Amgen comprises approximately 3.9% of Wilkinson Global Asset Management LLC’s holdings, making the stock its 12th largest position. Wilkinson Global Asset Management LLC’s holdings in Amgen were worth $49,432,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Dogwood Wealth Management LLC raised its stake in shares of Amgen by 275.0% in the 4th quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 55 shares in the last quarter. Anfield Capital Management LLC lifted its position in shares of Amgen by 1,000.0% during the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock worth $25,000 after purchasing an additional 70 shares during the last quarter. Tower View Wealth Management LLC grew its stake in Amgen by 331.6% in the first quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock worth $29,000 after purchasing an additional 63 shares in the last quarter. Manning & Napier Advisors LLC grew its stake in Amgen by 49.2% in the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock worth $32,000 after purchasing an additional 32 shares in the last quarter. Finally, Ares Financial Consulting LLC bought a new stake in Amgen in the fourth quarter valued at about $34,000. 76.50% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 2,970 shares of the business’s stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the sale, the senior vice president directly owned 7,340 shares in the company, valued at approximately $2,951,854.40. The trade was a 28.81% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Rachna Khosla sold 1,252 shares of the company’s stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $416.43, for a total transaction of $521,370.36. Following the completion of the sale, the senior vice president directly owned 6,404 shares of the company’s stock, valued at approximately $2,666,817.72. This represents a 16.35% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 6,222 shares of company stock worth $2,540,926. Company insiders own 0.85% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on AMGN shares. Canaccord Genuity Group upped their price objective on Amgen from $366.00 to $384.00 and gave the company a “hold” rating in a research note on Wednesday, August 5th. Argus decreased their target price on Amgen from $400.00 to $375.00 and set a “buy” rating for the company in a research report on Wednesday, May 20th. Wall Street Zen upgraded Amgen from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. Wells Fargo & Company upped their price target on Amgen from $390.00 to $400.00 and gave the company an “equal weight” rating in a research report on Wednesday, August 5th. Finally, The Goldman Sachs Group set a $389.00 price objective on Amgen in a research note on Friday, June 5th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, fifteen have issued a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat, Amgen has a consensus rating of “Hold” and a consensus target price of $372.39.

Check Out Our Latest Research Report on AMGN

Amgen Stock Performance

Shares of NASDAQ AMGN opened at $419.38 on Tuesday. The company has a current ratio of 1.37, a quick ratio of 1.13 and a debt-to-equity ratio of 4.44. The stock has a 50 day simple moving average of $372.05 and a 200-day simple moving average of $359.47. The company has a market cap of $226.73 billion, a PE ratio of 26.06, a P/E/G ratio of 3.86 and a beta of 0.41. Amgen Inc. has a 12-month low of $269.77 and a 12-month high of $421.79.

Amgen (NASDAQ:AMGN – Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.62 by $0.67. Amgen had a return on equity of 124.14% and a net margin of 22.95%.The business had revenue of $10.05 billion during the quarter, compared to analyst estimates of $9.43 billion. During the same period in the prior year, the company posted $6.02 EPS. The business’s revenue for the quarter was up 9.5% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, equities research analysts forecast that Amgen Inc. will post 22.78 EPS for the current year.

Amgen Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 11th. Stockholders of record on Friday, August 21st will be paid a $2.52 dividend. The ex-dividend date of this dividend is Friday, August 21st. This represents a $10.08 annualized dividend and a dividend yield of 2.4%. Amgen’s dividend payout ratio is presently 62.65%.

About Amgen

(Free Report)

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.